CD5 and neoplasm: Following engraftment with Eμ-TCL1 spleen-derived lymphocytes, mice were monitored until tumor expansion was witnessed (≥10% CD45+CD19+CD5+ peripheral blood lymphocytes [PBLs]), then randomly assigned to receive OPN5 or vehicle equivalent (VEH).